Abstract
Although there have been dramatic advances in clinical organ transplantation over the past 20 years, rejection, both acute and chronic, and the complications of immunosuppression remain major problems. Nevertheless as our understanding of the immune response to a vascularized organ allograft develops, so too will our ability to develop more specific immunosuppression. In any strategy for more specific immunosuppression compatibility for the major histocompatibility complex of antigens (HLA in man) is likely to be important. Monoclonal antibodies to T cell subpopulations, or even to T cells specifically activated by the graft, provide methods of suppressing the immune response at a more specific level. The recognition that stable grafts are maintained, at least in experimental rodent models, by T suppressor cells may allow development of precise methods of inducing the generation of such cells in clinical practice. The induction of tolerance in the adult animal can be achieved in a number of ways, the most promising of which for clinical application, is antigen pretreatment. If tolerance could be achieved in clinical practice within the not too distant future, then this would represent the attainment of the ultimate goal of transplantation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Peugh WN, Superina RA, Wood KJ, Morris PJ. The role of H-2 and non-H-2 antigens and genes in the rejection of murine cardiac allografts. Immunogenetics 1986; 23: 30–37.
Ting A, Morris PJ. Matching for B-cell antigens of the HLA-DR (D-related) series in cadaver renal transplantation. Lancer 1978; i: 575–577.
Ting A, Morris PJ. A powerful effect of HLA-DR matching on survival of cadaveric renal allografts. Lancet 1980; 2: 282–285.
Hart D, Fabre J. MHC antigens in rat kidney, ureter, and bladder: localization with monoclonal antibodies and demonstration of Ia positive dendritic cells. Transplantation 1981; 31: 318–325.
Mason D, Morris PJ. Effector mechanisms in allograft rejection. Ann Rev Immunol 1986; 4: 119–145.
Dallman MJ, Wood KJ, Morris PJ. Specific cytotoxic cells are found in the non-rejected kidneys of blood transfused rats. J Exp Med 1987; 165: 566–571.
Hutchinson IV. Suppressor T cells in allogeneic models. Transplantation 1986; 41: 547–555.
Dorf ME, Benaceraff B. Suppressor cells and immunoregulation. Ann Rev Immunol 1984; 2: 127–000.
Fuggle SV, McWhinnie DL, Chapman JR, Taylor HM, Morris PJ. Segmental analysis of HLA-class II antigen expression in human renal allografts: induction of tubular class II antigens and correlation with clinical parameters. Transplantation 1986; 42: 144–149.
Milton AD, Fabre JW. Massive induction of donortype class I and class II major histocompatibility complex antigens in rejecting cardiac allografts. J Exp Med 1986; 161: 98–112.
Wood KJ, Hopley A, Dallman MJ, Morris PJ. Induction of donor class I and class II major histocompatibility complex antigens does not always correlate with graft rejection. 1987; (submitted for publication).
Faustman DL, Steinman RM, Gebel HM, Haytfeld V, Davie JM, Laccy PE. Prevention of rejection of murine islet allografts by pretreatment with antidendritic cell antibody. Proc Natl Acad Sci 1984; 81: 3864–3868.
Reece-Smith H, McShane P, Morris PJ. Pretreatment of isolated adult islets with antibody effect on survival in allogeneic hosts. Transplantation 1983; 36: 228–230.
Jaffers GJ, Cosimi AB. Antilymphocyte globulin and monoclonal antibodies. In: Morris PJ, ed. Kidney Transplantation: Principles and Practice. 2nd edit. New York, London: Grune & Stratton 1984; 281–299.
Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. New Engl J Med 1985; 313: 337–000.
Cobbold SP, Waldmann H. Skin allograft rejection by L3T4 and Lyt-2+ T cell subsets. Transplantation 1986; 41: 634–639.
Madsen J, Peugh WN, Wood KJ, Morris PJ. The effect of anti-L3T4 monoclonal antibody treatment on first-set rejection of mouse cardiac allografts. Transplantation (in press).
Diamenstein T, Osawa H, Kirkman RL, Shapiro ME, Strom TB, Tilney NL, Kupiec-Weglinski JW. Interleukin 2 receptor—a target for immunosuppressive therapy. In: Morris PJ and Tilney NL, eds. Transplantation Reviews. New York: Grune & Stratton, 1987 (in press).
Billingham RE, Brent L, Medawar PB. Quantitative studies on Tissue Transplantation Immunity III. Actively acquired tolerance. Roy Soc (London), Philos Trans B 1956; 239: 375–414.
Burnett FM, Fenner F. The production of antibodies. 2nd edit. (Macmillan Melb.). 1949.
Opelz G. Blood transfusions in renal transplantation. In: Morris PJ, ed. Kidney Transplantation: Principles and Practice. 2nd edit. New York, London: Grune & Stratton, 1984; 323–334.
Hutchinson IV, Morris PJ. The role of major and minor histocompatibility antigens in active enhancement of rat kidney allograft survival by blood transfusion. Transplantation 1986; 41: 166–170.
Fabre J, Morris PJ. The effect of donor-strain blood pretreatment on renal allograft rejection in rats. Transplantation 1972; 14: 608–617.
Superina RA, Wood KJ, Morris PJ. The effect of pretreatment with a single cloned donor class I gene product on cardiac allograft survival in mice. Transplantation 1987 (in press).
Author information
Authors and Affiliations
Additional information
Members of the department who contributed to the work described in this lecture were M. Dallman, S. Fuggle, J. Madsen, G. Tellides, A. Ting and K. Wood
This paper is based on a lecture given at the 87th Annual Congress of the Japanese Surgical Society, Tokyo, Japan, 1987.
Rights and permissions
About this article
Cite this article
Morris, P.J. Advances in transplantation immunology. The Japanese Journal of Surgery 17, 323–333 (1987). https://doi.org/10.1007/BF02470630
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02470630